Gennev Medical Leadership and Credentials: An Independent Review

What Exactly Is Gennev and Who Runs Its Clinical Program?

Gennev is a women's telehealth company founded in Seattle in 2016 with a stated mission of making menopause care accessible. The clinical program is run through a network of licensed clinicians rather than a single named chief medical officer who is publicly active in research or policy. That absence of a high-profile medical director publishing peer-reviewed work is worth noting, because many women reasonably use academic output as a proxy for clinical rigor.

The platform employs board-certified OB-GYNs and advanced practice nurses, including practitioners who hold the NAMS Certified Menopause Practitioner (NCMP) credential. The NCMP designation requires passing a standardized examination administered by The Menopause Society (formerly NAMS) and demonstrates competency in diagnosing and managing menopause-related conditions. Holding this credential is a meaningful differentiator, because fewer than 1,200 clinicians in North America held NCMP status as of The Menopause Society's most recent count.

What the NCMP Credential Actually Means

The NCMP exam tests knowledge across vasomotor symptoms, genitourinary syndrome of menopause (GSM), cardiovascular risk, bone health, sexual health, mood, and the evidence base for hormone therapy (HT). A clinician who has passed this exam has demonstrated, at minimum, that she or he can apply current evidence correctly. Gennev's claim to employ NCMPs is therefore a substantive credential signal, not marketing language.

What Is Not Verified Independently

Gennev does not publish a publicly accessible roster of every clinician with license numbers, which is standard on some competitor platforms. You can verify any clinician's license through your state medical board directory. For example, the Washington Medical Commission and equivalent agencies in other states maintain searchable databases. If your Gennev clinician's name is provided at booking, cross-checking takes under two minutes and is always worth doing.

Is Gennev Legit? Accreditation, Licensing, and Legal Structure

Yes, Gennev operates through legitimately licensed medical entities, but "legit" requires unpacking because it covers several distinct layers.

State Licensing and the Corporate Practice of Medicine

Telehealth platforms in the United States cannot legally employ physicians directly in most states due to corporate-practice-of-medicine (CPOM) laws. Gennev, like most telehealth companies, uses a management services organization (MSO) model, where a separate physician-owned professional corporation holds the medical licenses and employs the clinicians. This is a standard, legal structure, not a loophole. Your prescriptions come from the licensed professional entity, not from Gennev Inc. Itself.

BBB Accreditation and Complaint History

Gennev has held Better Business Bureau (BBB) accreditation. BBB accreditation means a company has agreed to respond to consumer complaints and meet basic transparency standards. It is not a clinical quality seal. BBB ratings fluctuate based on complaint volume and response speed. Before enrolling, manage directly to Gennev's BBB profile and read the actual complaint text rather than just the letter grade. Patterns in complaints reveal more than the aggregate score: look for billing disputes, difficulty canceling subscriptions, and delays in prescription transmission, which are the three categories where telehealth menopause platforms most commonly receive negative reviews.

LegitScript and Pharmacy Safety

If Gennev sends prescriptions to a compounding or mail-order pharmacy, the pharmacy itself should carry LegitScript certification, which indicates compliance with U.S. Pharmacy laws and prescription requirements. Gennev has worked with PCAB-accredited compounding pharmacies for custom HRT formulations, though availability varies. Always confirm which pharmacy will fill your prescription and verify that pharmacy's accreditation independently.

What Gennev Treats: Life-Stage Coverage and Scope of Practice

Gennev is explicitly a midlife and menopause platform. It does not serve women who are pregnant, actively trying to conceive, or in the postpartum window. Understanding where it fits across the female life span prevents frustration.

Perimenopause (Typically Ages 40-51)

This is Gennev's primary sweet spot. Perimenopause can begin up to 10 years before the final menstrual period, and estrogen fluctuation during this window drives hot flashes, sleep disruption, cycle irregularity, mood changes, and early bone loss. Gennev clinicians can evaluate symptom burden, order labs (FSH, estradiol, TSH, lipids), and initiate hormone therapy where appropriate. The 2023 position statement from The Menopause Society on hormone therapy use in midlife women supports initiating HT in healthy women under 60 or within 10 years of menopause onset, which aligns with Gennev's prescribing window.

Post-Menopause

Women 12 or more months past their last period remain eligible for Gennev's services. Post-menopausal women face accelerated bone loss: trabecular bone density can decline 20-30% in the first 5-10 years after menopause. A telehealth platform that initiates or continues HT without also addressing bone density screening and falls risk is incomplete care. Ask your Gennev clinician specifically about DEXA screening eligibility, which the U.S. Preventive Services Task Force recommends at age 65 or earlier for women with risk factors.

Conditions Gennev Addresses

Beyond vasomotor symptoms, Gennev's scope includes:

• Genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTIs)
• Hypoactive sexual desire disorder (HSDD)
• Mood changes and anxiety linked to hormonal transition
• Weight gain and metabolic shifts in midlife
• Female pattern hair thinning related to estrogen decline
• Sleep disturbance

Women with PCOS entering perimenopause have a distinct hormonal picture. PCOS does not resolve at menopause; androgen excess and insulin resistance can persist and interact with declining estrogen in ways that require specialist-level interpretation. Ask specifically whether Gennev's clinicians have experience managing PCOS at midlife, as not all menopause practitioners have deep expertise here.

Hormone Therapy: What Gennev Prescribes and What the Evidence Says

Hormone therapy is Gennev's central clinical offering. Getting specific about what is prescribed matters because HT is not a single drug; it is a class with meaningful variation in route, dose, formulation, and risk profile.

FDA-Approved Options

Gennev prescribers can offer:

• Estradiol patches (e.g., Vivelle-Dot, Climara)
• Oral estradiol tablets
• Vaginal estradiol cream, ring, or tablet for local GSM treatment
• Progesterone (oral micronized progesterone such as Prometrium) for uterine protection in women with an intact uterus
• Testosterone (off-label in women; no FDA-approved female formulation exists in the U.S.)

Transdermal estradiol carries a lower venous thromboembolism risk than oral estrogen, a distinction supported by data from the E3N cohort study and confirmed in multiple subsequent analyses. This is a clinically meaningful difference: oral equine estrogens were associated with the cardiovascular signals in the Women's Health Initiative, while transdermal estradiol at lower doses was not directly studied in that trial.

Bioidentical and Compounded Hormones

Some women ask Gennev for compounded bioidentical hormone therapy (cBHT). The Endocrine Society's 2016 position and ACOG's guidance both state that compounded hormones lack the safety and efficacy testing of FDA-approved products and should not be routinely preferred. A responsible Gennev clinician should discuss this with you rather than defaulting to compounded formulations because of patient preference alone.

A useful framework for evaluating any telehealth menopause platform: ask whether they default to FDA-approved transdermal estradiol with oral micronized progesterone as a first-line standard, then deviate only with clinical rationale. Platforms that lead with compounded pellets or untested combinations without explaining the evidence gaps are a yellow flag.

Pregnancy, Lactation, and Contraception: What Every Gennev Patient Must Know

Hormone therapy as prescribed by Gennev is intended for menopausal and perimenopausal women. Several critical safety points apply.

Hormone Therapy Is Contraindicated in Pregnancy

Systemic estrogen and progesterone used for menopause symptom management are contraindicated in pregnancy. If you are perimenopausal and still ovulating, which can occur even with irregular cycles, pregnancy remains possible. Gennev should address contraception explicitly during your intake visit.

Perimenopause Does Not Equal Infertility

Women in perimenopause can and do conceive. Spontaneous pregnancy rates in women aged 40-44 who are still cycling are estimated at roughly 10-15% per year without contraception, and reliable ovulation can occur even when cycles are irregular. If you are not intending pregnancy and you are perimenopausal, your Gennev clinician should discuss contraception alongside HT.

Contraception Requirements

The ACOG recommendation is to continue contraception until 12 consecutive months without a period (menopause confirmation). Low-dose combined hormonal contraceptives or progestin-only methods can overlap with some HT goals. The levonorgestrel IUD can serve dual purposes: contraception and endometrial protection.

Lactation

Systemic HT is not indicated during lactation and can suppress milk supply. Women who are postpartum and breastfeeding should not use Gennev's HT services. For postpartum women experiencing vaginal dryness from lactational hypoestrogenism, low-dose local vaginal estrogen is generally considered safe while breastfeeding, but this decision requires in-person or high-quality telehealth evaluation, not a generic protocol.

Who Gennev Is Right For, and Who Should Look Elsewhere

A Good Fit

• Women 40 and older with vasomotor symptoms, GSM, or mood changes they attribute to hormonal transition
• Women who want insurance-covered telehealth rather than paying $250-500 for an in-person specialist visit
• Women in states without local NCMP-certified practitioners
• Women who have already been evaluated in person and want ongoing prescription management via telehealth

Not a Good Fit

• Women who are pregnant, actively trying to conceive, or breastfeeding
• Women with a history of hormone-sensitive cancers (breast, uterine) who need an oncology-informed discussion before HT
• Women with complex PCOS requiring fertility workup
• Women with undiagnosed vaginal bleeding, which requires in-person evaluation before initiating HT
• Women who need urgent mental health support; Gennev is not a crisis or psychiatric resource

Women with a personal or first-degree family history of breast cancer face a more nuanced HT decision. The 2023 Menopause Society position statement acknowledges that the absolute risk increase with short-term combined HT is small but real, and that decisions in this group require individualized counseling that goes deeper than a 20-minute telehealth intake allows.

Gennev Complaints: What Real Users Report

The most common complaint categories visible in public reviews and BBB filings fall into three patterns.

Billing and Insurance Surprises

Some users report that what appeared to be an insurance-covered visit resulted in unexpected out-of-pocket charges. This often reflects the complexity of insurance billing for telehealth: a visit may be covered but an associated lab or prescription may not be. Before your first appointment, call your insurer and confirm what is covered under your specific plan for a "telehealth women's health" visit.

Prescription Transmission Delays

A recurring frustration involves delays between a telehealth visit and a prescription arriving at the pharmacy. For women starting HT, a week's delay feels significant when symptoms are disrupting sleep and work. Ask Gennev at intake what the standard turnaround is and which pharmacy or platform they use.

Clinician Consistency

Some reviewers report being assigned different clinicians across visits, making it harder to build a longitudinal care relationship. Continuity matters in menopause care because symptom management requires iterative dose adjustments over months. Ask whether you can request a consistent provider.

How Gennev Compares on One Specific Metric: NAMS Certification Density

No telehealth menopause platform publicly discloses the exact percentage of their prescribing clinicians who hold NCMP certification. Based on review of public-facing clinician bios across Gennev, Midi Health, Alloy, and Evernow as of January 2025, Gennev lists NCMP credentials for a subset of practitioners but does not state a platform-wide percentage. Midi Health has made NCMP certification a stated hiring requirement for prescribers. That specific distinction is worth asking about directly: before your first Gennev visit, contact support and ask whether the clinician assigned to you holds NCMP certification. The answer is a concrete proxy for menopause-specific training depth.

The Evidence Gap: What Gennev Has Not Published

Gennev has not, as of this review, published peer-reviewed outcomes data from its patient population. That is not unique to Gennev; very few direct-to-consumer telehealth platforms publish clinical outcomes. But it means you cannot evaluate how effectively Gennev's care model actually reduces symptom burden, improves quality of life scores, or achieves treatment adherence compared to in-person care.

The MsFLASH network and the Study of Women's Health Across the Nation (SWAN) provide the richest longitudinal data on menopausal symptom burden in diverse women, and neither was conducted in a telehealth context. What works in a clinical trial setting with intensive follow-up may or may not translate to asynchronous telehealth. This is an honest evidence gap in the entire telehealth menopause space, not a Gennev-specific failing.

Women have historically been under-represented in cardiovascular and metabolic trials, and most long-term HT safety data comes from trials conducted in the 1990s and early 2000s using formulations (conjugated equine estrogen, medroxyprogesterone acetate) that differ from what Gennev now prescribes. Gennev's clinicians should be able to explain this nuance to you directly.

What to Ask Before Your First Gennev Appointment

Go into the intake visit with these specific questions:

1. Does my assigned clinician hold NCMP certification? What is their license number and state?
2. What is your first-line HT formulation, and why do you use that over alternatives?
3. How do you handle contraception in perimenopausal women who have not confirmed menopause?
4. What lab testing do you order at baseline, and which results would change your prescribing plan?
5. If I have a personal or family history of breast cancer, how do you approach HT differently?
6. What is your policy if I need urgent clinical guidance between scheduled visits?
7. Which pharmacy fills prescriptions, and what is typical turnaround time?

A Gennev clinician who can answer all seven questions specifically and without deflection is likely providing care at a level consistent with The Menopause Society's standard of practice. A clinician who gives vague answers to questions 2, 3, or 5 is a signal to request a different provider or seek a second opinion.